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doi:10.1016/j.ejvs.2010.02.009Abstract Objectives: To assess the current ‘real-world’ management of hospitalised patients
with lower-extremity peripheral artery disease (LE-PAD) and to assess the 1-year outcome.
Design, materials and methods: The prospective and multicentre registry COhorte des
Patients ARTe´riopathes (COPART) recruited consecutive patients from the departments of
vascular medicine of three academic hospitals in Southwestern France.
Results: Among the 940 patients, 27.4% had intermittent claudication (IC), 9.3% ischaemic rest
pain, 54.3% ulceration or gangrene and 9.3% acute limb ischaemia (ALI). Patients with IC were
younger and more likely to be men, with a history of smoking (89.5%) and chronic obstructive
pulmonary disease (17%). Among those with IC, 8.9% had bypass surgery and 41.5% were
treated with percutaneous angioplasty. Those with tissue loss had higher rates of cardiovas-
cular disease (CVD) risk factors and co-morbidities. At entry to the study, the level of control
of the CVD risk factors was poor. The 1-year mortality rate was of 5.7% in patients with IC,
23.1% in patients with ischaemic rest pain, 28.7% in patients with tissue loss and 23% in those
with ALI. Compliance with evidence-based medicine and pharmacological treatment was sub-
optimal.Me´decine Vasculaire, Hoˆpital Rangueil, 1, avenue du Professeur Jean Poulhe`s, TSA 50032, 31059
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578 J.P. Cambou et al.Conclusion: This registry underscores the differences in patient profiles in the daily clinical
setting, compared to those enrolled in several trials.
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peripheral artery disease (LE-PAD) is a source of
disability, mostly when it becomes clinically manifest, and
it is often associated with other cardiovascular diseases
(CVDs).1 In addition to the risk of limb loss and disability,
the general prognosis is poor, due to the high risk of
concomitant coronary artery disease (CAD) and cerebro-
vascular disease (CBVD) and the occurrence of fatal- and
non-fatal CVD ischaemic events.2e4
Data on epidemiology of LE-PAD in France are scarce.
Large registries comprising patients with LE-PAD are very
few,5e10 particularly with regard to hospitalised patients
affected by LE-PAD.11,12 Overall, data available on the
natural history of LE-PAD are mostly issued from studies
including patients with intermittent claudication. Few
studies have been performed in the field of ischaemic rest
pain or tissue-loss LE-PAD, especially in the modern area of
efficient preventive drug therapies (statins and renine
angiotensin system (RAS) inhibitors), as well as the
increasing use of distal re-vascularisation procedures.
Hospital registries allow the collection of epidemiolog-
ical data on a specific disease and scientific data on the
impact of different therapeutic approaches. In addition,
they provide a better understanding of the degree of
application of guidelines in the management of the disease.
The COhorte de Patients ARTe´riopathes (COPART) is
a registry collecting exhaustive data on all patients hospi-
talised for LE-PAD. This registry aims to improve knowledge
on the management of clinical LE-PAD in France and to
report the prognosis of these patients after discharge.
Materials and Methods
The COPART registry is a prospective multicentre study.
Patients were consecutively recruited initially from the
department of vascular medicine of Rangueil Hospital,
University of Toulouse, since June 2004. The registry has
been extended to the departments of vascular medicine in
Bordeaux (Saint-Andre´ Hospital, Bordeaux University) and
Limoges (Dupuytren University Hospital) since October
2006. In each centre, care to patients was provided
according to the usual practice without any change in
management strategy.
Inclusion criteria
To be included, each patient needed to meet the following
criteria: age >18 years, consent to participate into the
study and referred to the hospital specifically for clinical
LE-PAD of atherosclerotic origin. The clinical stages were to
be either intermittent claudication (IC), associated with an
abnormal ankleebrachial index (ABI) <0.90 or >1.30 or, in
case of a normal ABI at rest, a positive treadmill test
(Strandness protocol) and/or an arterial stenosis >50%
revealed by duplex ultrasound and/or angiography, orischaemic rest pain or ulceration and gangrene4 or acute
lower-limb ischaemia, related to a documented LE-PAD
with significant arterial stenosis. Cases with acute
ischaemia following bypass surgery or endovascular proce-
dures were also included.
Exclusion criteria
Patients whose follow-up was considered improbable, those
with arterial occlusive disease not related to atheroscle-
rosis (endofibrosis, inflammatory arterial disease, Buerger’s
disease, entrapment syndromes, etc.), those with acute
ischaemia without lower-limb atherosclerosis (embolic) and
patients refusing to participate were excluded from the
study.
Data collection
A computerised case-record form was filled-in for each
patient. The initial characteristics and the clinical and
therapeutic data on admission, during hospitalisation and
at discharge were collected. Similarly, clinical events
occurring during hospitalisation and within the first year of
follow-up were collected. The data collected at admission
included age, gender, CVD risk factors and LE-PAD clinical
presentation according to the Rutherford classification.13
CVD risk factors were defined as follows: diabetes was
defined by documented medical history, the use of oral
anti-diabetic agents or insulin or fasting plasma glucose
levels 1.26 g l; dyslipidaemia was defined by a docu-
mented medical history, use of lipid-lowering agents for
this purpose or fasting low-density lipoprotein (LDL)-
cholesterol 100 mg dl; hypertension was defined by
documented medical history and use of anti-hypertensive
drugs for this purpose, or systolic blood pressure (SBP)
140 mmHg or diastolic blood pressure (DBP) 90 mmHg at
admission determined by the average of the first two
measurements. Patients were considered as current
smokers if they were smoking at least one cigarette per
day. Patients were considered past-smokers if they had
stopped smoking since at least 1 month prior to inclusion in
the study. The following CVDs were noted, according to the
documented medical history: CAD heart failure, atrial
fibrillation, presence of a pacemaker at admission, CBVD
including ischaemic or haemorrhagic stroke as well as
transient ischaemic attack. Chronic kidney disease was
defined as previous history or noted according to the esti-
mated glomerular filtration rate (eGFR) according to the
Modification of Diet in Renal Disease (MDRD) Study equa-
tion, and chronic kidney disease was defined when eGFR
<60 ml min1 1.73 m2.
For the follow-up, the sequential procedure consisted of
consulting mortality data at registrar’s offices, mailing to
the family physicians and/or cardiologists/angiologists and,
finally, contacting the patients themselves, if necessary.
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each event leading to hospitalisation or death and were
analysed by a physician from the research group.
The primary outcome was total mortality. The secondary
outcomes were amputation, re-vascularisation during the
1-year follow up and a composite outcome combining
mortality, non-fatal myocardial infarction (MI) and non-
fatal stroke.
Statistical analysis
For quantitative variables, means and standard deviations
(SDs; or median for non-parametric data) are presented.
Discrete variables are presented as numbers and percent-
ages. Comparisons were made with chi-square test (or
Fisher’s exact tests, when appropriate) for discrete vari-
ables, and by KruskaleWallis test for continuous variables.
We used a polynomial regression analysis to test differences
between the three LE-PAD stages after adjustment for age.
In-hospital and 1-year survival rates after the index
hospitalisation were presented as percentages and
comparisons were made by chi-square tests. KaplaneMeierFigure 1 Flowchart of patiensurvival curves were used with log-rank test to compare the
1-year mortality in different subgroups. We used the Cox
regression model to assess the survival according to the LE-
PAD clinical presentation.
Results
From June 2004 to October 2008, 1009 patients with LE-PAD
were consecutively hospitalised in one of the three medical
centres of the COPART registry. The inclusion/exclusion of
hospitalised patients as well as clinical subtypes are pre-
sented in a flow-chart (Fig. 1). Overall, 940 patients were
included (608 patients from Toulouse, 129 from Bordeaux
and 203 from Limoges). Among them, 28 (3%) expired during
the in-hospital period. Among the 912 patients alive at
discharge, 649 have already reached the 1-year follow-up.
Table 1 shows the study population general characteris-
tics. Reasons for referral were IC (Rutherford grade I
category 3), ischaemic rest pain (Rutherford grade II cate-
gory 4), ulceration or gangrene (Rutherford Grades IIIeIV
category 5e6) and acute limb ischaemia (ALI) for referral in
27.2%, 9.3%, 54.3% and 9.3% of cases, respectively. Almostts e the COPART registry.
Table 1 Baseline characteristics of the study population.
Characteristics (n Z 940) N (%)
Men 675 (71.8)
Age (years mean  SD) 70.2  12.8
Age 75 years 395 (42.0)
Previous history
Coronary artery disease 359 (38.2)
Myocardial infarction 196 (20.9)
Cerebrovascular disease 143 (15.2)
Heart failure 112 (11.9)
Atrial fibrillation 182 (19.4)
Peripheral angioplasty 177 (18.8)
Peripheral bypass 173 (18.4)
Amputation 159 (16.9)
Chronic Kidney Disease 150 (16.0)
Cardiovascular risks factors
Hypertension 649 (69.0)
Hypercholesterolaemia 499 (53.1)
Current smokers 232 (24.7)
Ever smokers 709 (75.4)
Diabetes mellitus 413 (43.9)
Ankle-brachial index (n Z 764)
1.3 96 (12.6)
0.9e<1.3 41 (5.4)
0.7e<0.9 102 (13.4)
0.5e<0.7 187 (24.5)
<0.5 338 (44.2)
Treatment during the hospital stay
Bypass surgery 95 (10.1)
Angioplasty 285 (30.3)
Amputation 162 (17.2)
Drug therapies at discharge (n Z 903)
Antiplatelet agents (APA) 737 (81.6)
Aspirin 547 (60.6)
Clopidrogel 290 (32.1)
Statins 633 (70.0)
Angiotensin-converting enzyme
(ACE) inhibitors
365 (40.4)
Angiotensin II-receptor blockers (ARBs) 163 (18.1)
Beta-blockers 241 (26.7)
Vitamin K antagonists (VKA) 138 (15.3)
580 J.P. Cambou et al.one-half (44.2%) had an ABI < 0.50. Patients with Ruth-
erford grades IIIeIV had higher rates of diabetes (60%),
while patients with IC presented higher rates of dyslipi-
daemia and smoking (Fig. 2). A majority of these patients
had symptomatic multifocal CVD (Fig. 3). Patients with
Rutherford grades IIIeIV were more likely to have previous
history of CAD and/or CBVD, although this could be partly
explained by an older age.
Fig. 4 displays co-morbidities in LE-PAD patients according
to the Rutherford grade. A history of heart failure was more
frequent in patients with tissue loss (Rutherford grades IIIe
IV). A history of atrial fibrillation was more frequent among
participants with grades IIIeIV (24.1%) and ALI (27.6%).
Clinical and biological parameters at entry to the study
are shown in Table 2. One out of five patients was obese.Almost one-half had elevated systolic blood pressure
(47.7%). One-third had an LDL-cholesterol >100 mg dl1
and 39.5% had a high-density lipoprotein (HDL)-cholesterol
<40 mg dl1, especially in case of Grade IIIV. Similarly,
28.2% of the patients had an elevated blood glucose
1.26 g l1), mainly in the grades IIIeIV group.
Lower-limb angiography was performed in w60% of the
cohort and duplex ultrasound in w90% during hospital-
isation. Angioplasty was performed more frequently in
patients with claudication (41.0%) than in ischaemic rest
pain (28.7%) or tissue-loss grade patients (27.8%) The rates
of bypass surgery were comparable in different clinical
patterns More than one-quarter (24.8%) of patients with
Rutherford Grade IIeIV underwent amputation during the
hospital stay (including 15.0% above the ankle; Fig. 5).
At discharge, patients with grades II to IIIeIV or ALI
received statins, anti-platelet drugs, RAS inhibitors and
beta-blockers less often than IC patients. Full preventive
pharmacological therapies (statins, anti-platelet agents and
RAS inhibitors) were only prescribed in 53.5% of patients with
IC, 37.8% of those with ischaemic rest pain, 34.8% of those
with tissue loss and 28.6% of those who presented an ALI
(Fig. 6). In addition to the in-hospital mortality rate of 3%,
the 1-year mortality was at 21.4%, with consistent disparities
according to the LE-PAD clinical presentations (Table 3 and
Fig. 7). There was no statistical difference in mortality rates
according to treatment during the hospital stay: angioplasty
(20.7%) and bypass surgery (24.6%). Mortality was related to
CVDs in one-half of the cases. Adjusted for age, the total
mortality rate was four times higher in patients with grades
IIIeIV compared to those with grade I (hazard ratio (HR): 4.2,
standard error (SE): 1.5 (range: 2.1e8.4)) and in patients
with grade II (HR: 4.1, SE: 1.95 (95% confidence interval (CI):
1.6e10.3) and three times higher in patients with ALI (HR:
3.3, SE: 1.5 (1.3e8.0)).Discussion
In this report, we present the first results of an exhaustive
multicentre registry of patients managed in vascular
medicine departments of three university hospitals in the
southwest of France. One potential value of a registry is the
provision of information about patients who are generally
under-represented in randomised clinical trials, especially
women (28% in our study) and very old patients (42% > 75
years in this study). In contrast to other LE-PAD
cohorts,7,9,14 53% of the patients in this study had critical
limb ischaemia (grades IIIeIV). Of note, the registry
included only patients with IC whose clinical situation
required hospitalisation. Our patients had a severe risk
profile due to high rates of co-morbidities: CAD (38.4%),
atrial fibrillation (18.9%) and previous history of chronic
kidney disease (15%). Obviously, patients in this registry are
not comparable to the outpatients with atherothrombosis
enrolled in the Reduction of Atherothrombosis for
Continued Health (REACH) registry.10 Due to differences in
the study design and inclusion criteria, other CVDs were
more frequent in REACH than in the COPART registry. In
France, a cohort of 3811 patients with LE-PAD managed by
general practitioners has been reported in the ATTEST
study (ArTeriopaThie oblitErante des membres inferieurS
Figure 2 Cardiovascular risks factors according to the LE-PAD stages (nZ 940) ‘‘p’’Z age adjusted p with IC taken as reference
NS Z non significant *p value < 0.05. **p value < 0.01 ***p value < 0.001.
Figure 3 Coronary and cerebrovascular disease in LE-PAD patients (n Z 940) ‘‘p’’ Z age adjusted p with IC taken as reference
NS Z non significant *p value < 0.05 **p value < 0.01 ***p value < 0.001.
Figure 4 Co morbidity according to the LE-PAD clinical presentation groups (n Z 940) ‘‘p’’ Z age adjusted p with IC taken as
reference NS Z non significant *p value < 0.05 **p value < 0.01 ***p value < 0.001.
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Table 2 Clinical and biological parameters at entry according to the clinical presentation.
Grade I Grade II Grade IIIeIV Acute limb
ischaemia
(ALI) n (%)
Category 3
Intermittent
claudication n (%)
Category 4 Ischemic
rest pain n (%)
Category 5-6
Tissue loss n (%)
BMI 30 kg/m2 (n Z 713) 39/210 (18.6) 12/66 (18.2) 81/380 (21.3) 7/57 (12.3)
SBP (n Z 922)
<140 mmHg 135/251 (53.8) 45/84 (53.6) 262/502 (53.0) 40/85 (47.0)
140 < 160 mmHg 71/251 (28.3) 22/84 (26.2) 13/502 (26.1) 30/85 (35.3)
160 mmHg 45/251 (17.9) 17/84 (20.2) 109/502 (21.7) 15/85 (17.7)
DBP (n Z 922)
<80 mmHg 136/251 (54.6) 51/84 (60.7) 313/502 (62.6) 48/85 (56.5)
80 < 90 mmHg 88/251 (35.1) 23/84 (27.4) 141/502 (28.2) 22/85 (25.9)
90 mmHg 26/251 (10.4) 10/84 (11.9) 46/502 (9.2) 15/85 (17.2)
HDL-cholesterol <40 mg/dl (n Z 537) 47/148 (31.8) 20/49 (40.8) 172/303 (56.8)*** 131/303 (43.2)
LDL-cholesterol 100 mg/dl (n Z 528) 67/143 (46.9) 17/46 (37.0) 98/302 (32.5)* 13/37 (35.1)
Triglycerides  1.50 g/l (n Z 629) 73/172 (42.4) 24/57 (42.1) 115/357 (32.2) 9/43 (20.9)**
Glycaemia  1.26 g/l (n Z 783) 37/213 (17.4) 19/73 (26.0) 147/428 (34.7)* 18/69 (26.1)
CRP us  6.4 UI (n Z 741) 67/169 (39.6) 42/68 (61.8)*** 381/440 (86.6)*** 51/64 (79.7)**
Chronic Kidney Disease (n Z 820) 64/231 (27.7) 34/80 (42.5) 295/449 (64.5)** 34/69 (49.2)*
p Z age adjusted p with grade I (IC) taken as reference.
*p value < 0.05, **p value < 0.01, ***p value < 0.001.
Figure 5 Treatment during the hospital stay (n Z 940) ‘‘p’’ Z age adjusted p with IC taken as reference NS Z non significant
*p value < 0.05 **p value < 0.01 ***p value < 0.001.
Figure 6 Treatment at discharge (nZ 903) Patient alive at discharge and with treatment known ‘‘p’’Z age adjusted p with IC
taken as reference NS Z non significant *p value < 0.05 **p value < 0.01 ***p value < 0.001.
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Table 3 One-year outcome n Z 649.a
Grade I Grade II Grade IIIeIV Acute limb
ischemia
(ALI) n (%)
Category 3
Intermittent
claudication n (%)
Category 4
Ischemic
rest pain n (%)
Category 5-6 Tissue
loss n (%)
n Z 177 n Z 52 n Z 359 n Z 61
Total death 10 (5.7) 12 (23.1)** 103 (28.7)*** 14 (23.0)**
Cardiovascular death 4 (2.3) 5 (9.6) 54 (15.0)** 9 (14.8)**
Total death or non-fatal myocardial
infarction or non-fatal stroke
14 (7.9) 13 (25.0)** 109 (30.4)*** 15 (24.6)*
Angioplasty or bypass
surgery after discharge
21 (11.9) 11 (21.2)* 39 (10.9) 1 (1.6)
Amputation after discharge 3 (1.7) 12 (23.1)*** 89 (24.2)*** 9 (14.8)***
Age adjusted p value with grade I (IC) taken as reference.
*p value < 0.05, **p value < 0.01, ***p value < 0.001.
a Patients with a one-year follow-up.
LE-PAD in France: The COPART Registry 583chez les paTients en medecine ge´ne`rale).8 Those with iso-
lated LE-PAD (without other clinical CVD) presented higher
rates of smoking and dyslipidaemia than in the COPART
cohort. As a result, more diabetic and hypertensive
patients are reported in COPART. The results of our registry
can also be used to assess the compliance with evidence-
based medicine and guidelines. Statins were given at
discharge in >70% of LE-PAD patients, anti-platelet agents
were commonly used, but the prescription of angiotensin-
converting enzyme (ACE)-inhibitors and beta-blockers
were sub-optimal. The evidence-based therapies (statins,
anti-platelet agents and RAS inhibitors) were fully
prescribed in only 40% of the patients. Regarding the use of
anti-platelet therapies, these non-conformities were partly0.
60
0.
80
1.
00
0 5
analysis time
diagfinalRuth = Grade I
diagfinalRuth = Grade III-IV
P value < 0.001 
0                 5               
Analysis 
Number of paen
Month 0 1 2 3 4 5 6 
Grade I 177 177 177 177 175 175 173 
Grade II 52 51 48 47 46 45 45 
Grade III-IV 359 335 321 309 298 288 283 
ALI 61 56 56 54 52 50 49
Figure 7 One-year Kaplan Meier survival curves (Total death) acco
taken as reference.explained by different rates of use of vitamin-K antagonists
(VKAs). Paradoxically, the use of these therapies was even
lower in more severe cases of LE-PAD, with grades IIeIV of
disease. The rate of use of these major therapies was even
lower in the Dutch cohort of hospitalised patients,7
although this could be explained by the fact that the
latter enrolled the patients from 1990 to 2005, before the
LE-PAD international guidelines.4 The prescription rates of
these four major drug groups in COPART are quite similar to
the French arm of the REACH registry.10 Conversely, higher
rates of use of beta-blockers are reported in the REACH
registry (49.3% vs. 26.7%)
In our study, the prognosis of patients is poor, with
dramatic 1-year mortality at 21.4%, including CVD death in10 15
diagfinalRuth = Grade II
diagfinalRuth = Isch.aigue
Grade I (IC) 94.9%  
Grade II (Ischaemic rest pain) 76.9% 
Grade III-IV (Tissue loss) 71.3%
Acute limb ischaemia 77.1 %
ALI 
         10     11 13             15      
me   
ts at risk:
7 8 9 10 11 12 13 
173 173 171 171 170 105 58 
45 45 44 43 42 38 14 
275 266 265 263 260 174 90 
49 48 48 48 48 45 20
rding to LE-PAD stages (nZ 649) ‘‘p’’Z age adjusted p with IC
584 J.P. Cambou et al.one-half of the cases. In an Italian registry of patients with
critical limb ischaemia,2 the reported mortality rates
(19.1%) were lower than in our grades IIIeIV patients
(28.7%). In clinical trials comprising patients with LE-
PAD,15,16 mortality and CVD-events rates are quite also
lower. In other series, including mainly patients with IC, the
mortality and major cardiovascular events rates are also
lower than in our registry. Actually, patients with less
severe disease, requiring ambulatory medical treatment,
are beyond the scope of our study. This could even explain
the surprisingly high 1-year amputation rate of 1.7% in
patients with IC. In contrast, the high amputation rate at
25% in the more severe LE-PAD cases is comparable to the
rate in other hospital series.4 The poor level of manage-
ment of CVD risk factors at admission has also been pre-
sented in other reports.7,14,17e20 Given the high rates of
fatal and non-fatal events, further efforts should be made
to improve the secondary prevention in the patients.
In conclusion, this French multicentre registry provides
‘real word’ data on current treatment and outcomes of LE-
PAD hospitalised patients in university hospitals in France.
Our results highlight important prognosis differences
according to the clinical stage and the worse CVD risk
profile in case of ischaemic rest pain or tissue loss, partly
explained by older age of such patients. Our patients were
also mostly affected by other CVDs (CADs and cerebral
artery diseases) and had an unsatisfactory level of CVD risk-
factors management. Their prognosis is dramatically poor.
Compliance with evidence-based medicine was sub-
optimal, particularly with a low level of use of RAS
inhibitors. An adequate control of CVD risk factors is highly
recommended to reduce the very high incidence of fatal
and non-fatal events. In addition, the COPART registry
underscores the differences in patients’ profiles in the daily
clinical setting, compared to patients with LE-PAD enrolled
in several trials. As for illustration, recent findings on the
lack of effectiveness of statins21,22 in very advanced
conditions, such as heart failure or end-stage renal disease,
highlight the necessity to re-assess the major therapies
used for the secondary prevention in the specific field of
progressed LE-PAD, especially in case of rest pain ischaemia
or tissue-loss LE-PAD group.
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